SIGA Technologies
Nasdaq SIGA · New York, NY
Works in Infectious disease
SIGA Technologies is a clinical trial sponsor based in New York, NY, listed as Nasdaq SIGA. It has 1 active clinical trial with 100 planned participants, in Infectious disease. Since 2021 it has completed 7 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq SIGA
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about SIGA Technologies
SIGA Technologies is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 100 planned participants, in Infectious disease. Since 2021 it has completed 7 trials and stopped 1 early.
SIGA Technologies is based in New York, NY and is listed as Nasdaq SIGA. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with SIGA Technologies; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-01.
Approve Suite is not affiliated with SIGA Technologies. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.